Home Nitros Benzamide, 2-hydroxy-N-(5-nitro-2-thiazolyl)-

Benzamide, 2-hydroxy-N-(5-nitro-2-thiazolyl)-

CAS No.:
173903-47-4
Catalog Number:
AG001Z9L
Molecular Formula:
C10H7N3O4S
Molecular Weight:
265.2453
Pack Size
Purity
Availability
Location
Price(USD)
Quantity
  
1g
98%(HPLC)
In Stock USA
United States
$239
- +
5g
98%(HPLC)
In Stock USA
United States
$678
- +
25g
98%(HPLC)
In Stock USA
United States
$1990
- +
Product Description
Catalog Number:
AG001Z9L
Chemical Name:
Benzamide, 2-hydroxy-N-(5-nitro-2-thiazolyl)-
CAS Number:
173903-47-4
Molecular Formula:
C10H7N3O4S
Molecular Weight:
265.2453
MDL Number:
MFCD07484970
IUPAC Name:
2-hydroxy-N-(5-nitro-1,3-thiazol-2-yl)benzamide
InChI:
InChI=1S/C10H7N3O4S/c14-7-4-2-1-3-6(7)9(15)12-10-11-5-8(18-10)13(16)17/h1-5,14H,(H,11,12,15)
InChI Key:
FDTZUTSGGSRHQF-UHFFFAOYSA-N
SMILES:
O=C(c1ccccc1O)Nc1ncc(s1)[N+](=O)[O-]
UNII:
15KFG88UOJ
NSC Number:
697856
Properties
Complexity:
336  
Compound Is Canonicalized:
Yes
Covalently-Bonded Unit Count:
1  
Defined Atom Stereocenter Count:
0
Defined Bond Stereocenter Count:
0
Exact Mass:
265.016g/mol
Formal Charge:
0
Heavy Atom Count:
18  
Hydrogen Bond Acceptor Count:
6  
Hydrogen Bond Donor Count:
2  
Isotope Atom Count:
0
Molecular Weight:
265.243g/mol
Monoisotopic Mass:
265.016g/mol
Rotatable Bond Count:
2  
Topological Polar Surface Area:
136A^2
Undefined Atom Stereocenter Count:
0
Undefined Bond Stereocenter Count:
0
XLogP3:
3.2  
Literature
Title Journal
Validated and optimized high-performance liquid chromatographic determination of tizoxanide, the main active metabolite of nitazoxanide in human urine, plasma and breast milk. Journal of chromatographic science 20120701
Development of a method by UPLC-MS/MS for the quantification of tizoxanide in human plasma and its pharmacokinetic application. Bioanalysis 20120501
Nitazoxanide stimulates autophagy and inhibits mTORC1 signaling and intracellular proliferation of Mycobacterium tuberculosis. PLoS pathogens 20120501
Tizoxanide pyridine monosolvate. Acta crystallographica. Section E, Structure reports online 20120501
WormAssay: a novel computer application for whole-plate motion-based screening of macroscopic parasites. PLoS neglected tropical diseases 20120101
Effects of doxycycline on gene expression in Wolbachia and Brugia malayi adult female worms in vivo. Journal of biomedical science 20120101
Current status and future directions in the management of chronic hepatitis C. Virology journal 20120101
Thiazolides as novel antiviral agents. 2. Inhibition of hepatitis C virus replication. Journal of medicinal chemistry 20111222
Antiviral activity of substituted salicylanilides--a review. Mini reviews in medicinal chemistry 20111001
Synthesis and biological evaluation of substituted 4-arylthiazol-2-amino derivatives as potent growth inhibitors of replicating Mycobacterium tuberculosis H₃₇Rv. Bioorganic & medicinal chemistry letters 20110915
Thiazolides as novel antiviral agents. 1. Inhibition of hepatitis B virus replication. Journal of medicinal chemistry 20110623
Identification of a host cell target for the thiazolide class of broad-spectrum anti-parasitic drugs. Experimental parasitology 20110601
Synthesis of benzologues of Nitazoxanide and Tizoxanide: a comparative study of their in vitro broad-spectrum antiprotozoal activity. Bioorganic & medicinal chemistry letters 20110515
Tissue and stage-specific distribution of Wolbachia in Brugia malayi. PLoS neglected tropical diseases 20110501
Antiviral drugs against hepatitis C virus. Genetic vaccines and therapy 20110101
Simultaneous spectrophotometric estimation of nitazoxanide and ofloxacin in tablets. Indian journal of pharmaceutical sciences 20110101
New treatments for chronic hepatitis C. The Korean journal of hepatology 20100901
A screening pipeline for antiparasitic agents targeting cryptosporidium inosine monophosphate dehydrogenase. PLoS neglected tropical diseases 20100801
Antiviral treatment of chronic hepatitis B virus (HBV) infections. Viruses 20100601
The pharmacokinetics of nitazoxanide active metabolite (tizoxanide) in goats and its protein binding ability in vitro. Journal of veterinary pharmacology and therapeutics 20100401
Antiviral therapy for hepatitis C virus: beyond the standard of care. Viruses 20100401
Subarachnoidal Neurocysticercosis non-responsive to cysticidal drugs: a case series. BMC neurology 20100101
In Vitro Susceptibility of Canine Influenza A (H3N8) Virus to Nitazoxanide and Tizoxanide. Veterinary medicine international 20100101
Hepatitis C and kidney disease. Hepatitis research and treatment 20100101
Thiazolides, a new class of anti-influenza molecules targeting viral hemagglutinin at the post-translational level. The Journal of biological chemistry 20091023
Nitazoxanide kills replicating and nonreplicating Mycobacterium tuberculosis and evades resistance. Journal of medicinal chemistry 20091008
Sensitive high performance liquid chromatographic assay for nitazoxanide metabolite in plasma. Die Pharmazie 20090701
Nitazoxanide, tizoxanide and a new analogue [4-nitro-N-(5-nitro-1,3-thiazol-2-yl)benzamide; NTB] inhibit the growth of kinetoplastid parasites (Trypanosoma cruzi and Leishmania mexicana) in vitro. The Journal of antimicrobial chemotherapy 20090601
Prophylactic and therapeutic efficacy of nitazoxanide against Cryptosporidium parvum in experimentally challenged neonatal calves. Veterinary parasitology 20090309
Brugia malayi: Effects of nitazoxanide and tizoxanide on adult worms and microfilariae of filarial nematodes. Experimental parasitology 20090101
Distribution of Brugia malayi larvae and DNA in vector and non-vector mosquitoes: implications for molecular diagnostics. Parasites & vectors 20090101
Liquid chromatography-tandem mass spectrometry analysis of nitazoxanide and its major metabolites in goat. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20081115
New advances in the treatment of Clostridium difficile infection (CDI). Therapeutics and clinical risk management 20081001
Neospora caninum: functional inhibition of protein disulfide isomerase by the broad-spectrum anti-parasitic drug nitazoxanide and other thiazolides. Experimental parasitology 20080101
Nitazoxanide, tizoxanide and other thiazolides are potent inhibitors of hepatitis B virus and hepatitis C virus replication. Antiviral research 20080101
Induction of tachyzoite egress from cells infected with the protozoan Neospora caninum by nitro- and bromo-thiazolides, a class of broad-spectrum anti-parasitic drugs. International journal for parasitology 20070801
In vitro efficacy of nitro- and bromo-thiazolyl-salicylamide compounds (thiazolides) against Besnoitia besnoiti infection in Vero cells. Parasitology 20070701
Efficacy of nitazoxanide, tizoxanide and tizoxanide/albendazole sulphoxide combination against Taenia crassiceps cysts. The Journal of antimicrobial chemotherapy 20070201
Bioequivalence study of a fixed dose combination of nitazoxanide and ofloxacin in Indian healthy volunteers. Arzneimittel-Forschung 20070101
Nitazoxanide pharmacokinetics and tolerability in man using single ascending oral doses. International journal of clinical pharmacology and therapeutics 20020501
Nitazoxanide pharmacokinetics and tolerability in man during 7 days dosing with 0.5 g and 1 g b.i.d. International journal of clinical pharmacology and therapeutics 20020501
In vitro activity of nitazoxanide and related compounds against isolates of Giardia intestinalis, Entamoeba histolytica and Trichomonas vaginalis. The Journal of antimicrobial chemotherapy 20020101
Efficacy of nitazoxanide, tizoxanide and tizoxanide glucuronide against Cryptosporidium parvum development in sporozoite-infected HCT-8 enterocytic cells. The Journal of antimicrobial chemotherapy 20000701
Screening of compounds for antimicrosporidial activity in vitro. Folia parasitologica 19980101
Properties